Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
NIACOR vs NIASPAN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Niacin (nicotinic acid) reduces VLDL and LDL synthesis by inhibiting lipolysis in adipose tissue, decreasing free fatty acid flux to the liver, and inhibiting hepatic triglyceride synthesis. It also increases HDL by reducing catabolism of apolipoprotein A-I.
Niacin (nicotinic acid) reduces hepatic production of VLDL and LDL, and increases HDL by inhibiting diacylglycerol acyltransferase-2 (DGAT2) and reducing hepatic triglyceride synthesis. It also decreases the catabolism of HDL apolipoproteins A-I and A-II.
Adjunct to diet for reduction of elevated total cholesterol, LDL-C, apo B, and triglyceride levels, and to increase HDL-C in primary hypercholesterolemia and mixed dyslipidemia,Adjunct to diet for reduction of risk of recurrent myocardial infarction in patients with coronary artery disease and hypercholesterolemia,Adjunct to diet for slowing progression of coronary atherosclerosis,Off-label: treatment of pellagra (niacin deficiency)
Primary dyslipidemia and mixed dyslipidemia as an adjunct to diet,Hypertriglyceridemia in patients at risk of pancreatitis,Reduction of risk of myocardial infarction in patients with hyperlipidemia and history of MI,Secondary prevention of cardiovascular events in combination with statin,Off-label: Prevention of pellagra (niacin deficiency)
Initial: 250 mg orally once daily after evening meal; titrate up by 250–500 mg/day every 2–4 weeks. Maintenance: 1–2 g/day in divided doses (2–3 times daily). Maximum: 6 g/day.
Starting dose: 500 mg orally once daily at bedtime; after 4 weeks, increase to 1000 mg once daily; then titrate to maintenance dose of 1500-2000 mg once daily; maximum dose: 2000 mg/day.
20–45 minutes for immediate-release niacin; terminal half-life of main metabolites (nicotinuric acid) is approximately 1.5–4 hours; short half-life necessitates multiple daily dosing for lipid effects
Terminal half-life is 20-45 minutes (immediate-release) but due to prolonged release formulation of Niaspan, the half-life is extended to 2-4 hours for total nicotinic acid and 12 hours for nicotinuric acid, allowing once-daily dosing.
Hepatic metabolism via two pathways: conjugation with glycine to form nicotinuric acid (major, low-affinity high-capacity) and oxidation to N-methylnicotinamide and other metabolites (minor, high-affinity low-capacity). Enzymes involved: nicotinamide N-methyltransferase (NNMT) and aldehyde oxidase.
Primarily hepatic metabolism via two pathways: conjugation with glycine to form nicotinuric acid (major pathway, saturable) and conversion to nicotinamide adenine dinucleotide (NAD). Minor metabolism via oxidation to N-methylnicotinamide and other metabolites.
Renal: 60-88% as unchanged drug and metabolites after oral administration; fecal: <2%
Primarily renal (60-76% as unchanged drug and metabolites). Hepatic metabolism is extensive; less than 2% excreted in feces.
<20% bound to albumin; minimal binding to other plasma proteins
<20% bound to plasma proteins (mainly albumin). Binding is negligible at therapeutic concentrations.
0.5–0.7 L/kg; indicates distribution into total body water and some tissue binding
Approximately 0.5 L/kg (around 35 L in a 70 kg adult), indicating distribution into total body water.
Oral immediate-release: 60–76% (variable due to first-pass metabolism); sustained-release: lower bioavailability (50–60%) due to increased presystemic metabolism
Oral (extended-release): ~60-76% due to extensive first-pass metabolism. Bioavailability is dose-dependent and saturable at higher doses.
No specific adjustment recommended; use caution in severe renal impairment (Cr Cl <30 m L/min) due to potential accumulation; consider reducing dose or prolonging interval.
No specific dose adjustment provided by manufacturer; use with caution in patients with renal impairment; avoid in patients with severe renal impairment or nephrotic syndrome.
Contraindicated in Child-Pugh class B and C; use with caution in mild impairment (Child-Pugh A) with dose reduction of 50% initially.
Contraindicated in patients with significant or unexplained hepatic dysfunction; use with caution in patients with Child-Pugh class A, avoid in Child-Pugh class B or C.
For hyperlipidemia (off-label): Initial 50–100 mg/kg/day orally divided into 2–3 doses; titrate over 4–6 weeks up to 200–300 mg/kg/day; maximum 6 g/day. Not recommended in children <2 years.
Safety and efficacy not established in pediatric patients; not recommended for use.
Start at lowest dose (250 mg daily); titrate slowly due to increased risk of flushing, hypotension, and hepatotoxicity; monitor liver function and glucose closely.
No specific dose adjustment recommended; monitor for adverse effects such as myopathy and hepatotoxicity; initiate at low end of dosing range.
None.
No FDA black box warning.
Hepatotoxicity: elevated liver enzymes, hepatitis; discontinue if persistent elevations occur,Flushing: prostaglandin-mediated, can be reduced by taking aspirin prior; tolerance develops,Hyperuricemia: may precipitate gout,Hyperglycemia: may increase blood glucose; use with caution in diabetes,Peptic ulcer disease: reactivation may occur,Hypotension: can occur, especially with vasoactive drugs
Hepatotoxicity: elevated liver enzymes, rare severe hepatotoxicity; avoid in patients with active liver disease,Flushing: prostaglandin-mediated, can be reduced by taking aspirin or starting with low doses,Hyperglycemia: may increase blood glucose, use with caution in diabetic patients,Hyperuricemia: may precipitate gout, monitor uric acid,Gastrointestinal effects: can cause peptic ulcer, use caution with history of GI bleeding,Cardiovascular: may cause hypotension, especially with concurrent use of antihypertensives
Hypersensitivity to niacin or any component of formulation,Significant or unexplained hepatic dysfunction,Active peptic ulcer disease,Arterial hemorrhage
Active liver disease or unexplained transaminase elevations,Active peptic ulcer disease,Arterial bleeding,Hypersensitivity to niacin or any component of the formulation
Avoid high-fat meals as they may increase risk of flushing. Take with low-fat snack. Alcohol and hot drinks can exacerbate flushing.
Avoid alcohol, hot beverages, and spicy foods near dose time as they can worsen flushing. Take with a low-fat snack (e.g., apple, rice cakes) to reduce gastrointestinal upset and flushing. Avoid high-fat meals which may increase risk of flushing. Grapefruit juice has no significant interaction but other fruit juices have not been studied; advise moderate intake.
FDA Pregnancy Category C. Niacin is not recommended for use in pregnant women due to potential fetal harm, though no well-controlled studies exist. In animal studies, high doses have caused fetal abnormalities. First trimester: Avoid use due to theoretical risk of teratogenicity. Second and third trimesters: Use only if clearly needed, as niacin can cause vasodilation and potential hypotension, which may reduce uteroplacental perfusion.
Niacin (NIASPAN) is classified as FDA Pregnancy Category C. Animal studies have shown adverse effects at high doses, but there are no adequate and well-controlled studies in pregnant women. Niacin should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. There is no evidence of teratogenicity in humans at recommended doses, but high doses may cause fetal harm.
Niacin is excreted into human breast milk in minimal amounts; M/P ratio unknown. The American Academy of Pediatrics considers niacin compatible with breastfeeding. However, high maternal doses may lead to adverse effects in the infant due to potential accumulation. Caution is advised; monitor infant for flushing or gastrointestinal disturbances.
Niacin is excreted in human breast milk in amounts that are likely comparable to maternal plasma levels. The milk-to-plasma (M/P) ratio for niacin is approximately 1.0. The American Academy of Pediatrics considers niacin compatible with breastfeeding at usual dietary intakes, but high pharmacological doses should be avoided due to potential adverse effects in the infant, such as flushing and gastrointestinal disturbances.
No specific dose adjustments recommended due to lack of pharmacokinetic studies in pregnant women. However, physiological changes in pregnancy (increased plasma volume, renal clearance) may reduce niacin levels, potentially requiring dose increase. Use the lowest effective dose and avoid extended-release formulations due to higher hepatotoxicity risk. Usual adult doses (500-2000 mg/day) may be used with caution.
No specific dose adjustments are recommended for niacin during pregnancy due to lack of data on pharmacokinetic changes. However, doses should be kept at the lowest effective level and used only when clearly needed. There is no evidence that pregnancy alters niacin clearance or requires dose modification.
Niacor (niacin) can cause profound flushing, which may be mitigated by taking aspirin 30 minutes prior or using extended-release formulations. Monitor liver function and blood glucose, as niacin can elevate transaminases and worsen glycemic control. Patients with gout may experience increased uric acid levels.
Niacin extended-release (NIASPAN) causes flushing, which can be mitigated by taking aspirin 30 minutes before dosing, avoiding alcohol and hot beverages at time of dosing, and initiating at low dose with gradual titration. Liver function tests must be monitored; elevation >3x ULN requires discontinuation. NIASPAN can exacerbate gout by increasing uric acid levels; check uric acid at baseline and periodically. Use with caution in diabetes as it may increase glucose levels. Avoid in patients with active liver disease, unexplained transaminase elevations, or peptic ulcer disease.
Take with food to reduce stomach upset.,Do not crush or chew extended-release tablets.,Flushing is common and may decrease with continued use.,Avoid alcohol and hot beverages near dosing time to reduce flushing.,Report unexplained muscle pain, tenderness, or weakness.,Monitor blood sugar if diabetic.,Do not substitute with dietary supplements without doctor approval.
Take NIASPAN at bedtime with a low-fat snack to reduce flushing.,Do not take on an empty stomach; avoid alcohol and hot drinks near dose time.,Flushing may occur but usually decreases over weeks; can take aspirin 30 minutes prior to dose.,Do not miss doses; if a dose is missed, do not double up the next day.,Common side effects include flushing, itching, and tingling; report severe or persistent effects.,Your doctor will monitor blood glucose, uric acid, and liver function regularly.,Do not substitute with other niacin preparations without doctor approval.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about NIACOR vs NIASPAN, answered by our medical review team.
NIACOR is a Antilipemic agent that works by Niacin (nicotinic acid) reduces VLDL and LDL synthesis by inhibiting lipolysis in adipose tissue, decreasing free fatty acid flux to the liver, and inhibiting hepatic triglyceride synthesis. It also increases HDL by reducing catabolism of apolipoprotein A-I.. NIASPAN is a Antilipemic agent that works by Niacin (nicotinic acid) reduces hepatic production of VLDL and LDL, and increases HDL by inhibiting diacylglycerol acyltransferase-2 (DGAT2) and reducing hepatic triglyceride synthesis. It also decreases the catabolism of HDL apolipoproteins A-I and A-II.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between NIACOR and NIASPAN depend on the specific clinical indication. These are both Antilipemic agent agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of NIACOR is: Initial: 250 mg orally once daily after evening meal; titrate up by 250–500 mg/day every 2–4 weeks. Maintenance: 1–2 g/day in divided doses (2–3 times daily). Maximum: 6 g/day.. The standard adult dose of NIASPAN is: Starting dose: 500 mg orally once daily at bedtime; after 4 weeks, increase to 1000 mg once daily; then titrate to maintenance dose of 1500-2000 mg once daily; maximum dose: 2000 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between NIACOR and NIASPAN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. NIACOR is classified as Category C. FDA Pregnancy Category C. Niacin is not recommended for use in pregnant women due to potential fetal harm, though no well-controlled studies exist. In animal studies, high doses ha. NIASPAN is classified as Category C. Niacin (NIASPAN) is classified as FDA Pregnancy Category C. Animal studies have shown adverse effects at high doses, but there are no adequate and well-controlled studies in pregna. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.